Company profile
Nu-Med Plus, Inc.
OTC: NUMD · Healthcare · Medical - Devices
#1166 of 1,422 Healthcare companies by revenue
EA Score
23DFH 4DQ 49GM —SS 31
v0.1 · 55/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$56.2k
Employees
2
as of 2026-08-25
Market cap
$2.0M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02020
Net income-$56.2k-$56.2k2025
Operating income-$49.0k-$49.0k2025
Total assets$7.9k$7.9k2025
Liabilities$279.2k$279.2k2025
Equity-$271.3k-$271.3k2025
Revenue trend
FY2013 – FY2020 · USD
FY13
FY14
FY15
FY16
FY17
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Nu-Med Plus, Inc.’s revenue?
Nu-Med Plus, Inc. booked $0 in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
VitaSpring Biomedical Co. Ltd.18DPsyence Group Inc.——Lifeline Biotechnologies, Inc.——Genprex, Inc.34DiMD Companies, Inc.47DTelo Genomics Corp.——Neighbors
Salt Lake →Key facts
CEOWilliam R. Colvin
SectorHealthcare
IndustryMedical - Devices
HeadquartersSalt Lake City, UT
ExchangeOTC: NUMD
Employees2
IPO date2014-09-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.